Holen Sie sich die Stockscreener-App
55.45
16.57%
7.88
Vorhandelsmarkt:
53.18
-2.27
-4.09%
Schlusskurs vom Vortag:
$47.57
Offen:
$46.2
24-Stunden-Volumen:
15.02M
Relative Volume:
10.42
Marktkapitalisierung:
$11.42B
Einnahmen:
$2.04B
Nettoeinkommen (Verlust:
$373.39M
KGV:
32.69
EPS:
1.6961
Netto-Cashflow:
$495.96M
1W Leistung:
+17.48%
1M Leistung:
+21.65%
6M Leistung:
+14.66%
1J Leistung:
+17.20%
1-Tages-Spanne:
$46.07
$57.81
1-Wochen-Bereich:
$46.07
$57.81
52-Wochen-Spanne:
$37.74
$57.81
Qiagen Nv Stock (QGEN) Company Profile
Firmenname
Qiagen Nv
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie QGEN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
QGEN
Qiagen Nv
|
55.45 | 9.80B | 2.04B | 373.39M | 495.96M | 1.6961 |
|
TMO
Thermo Fisher Scientific Inc
|
619.01 | 232.46B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
234.33 | 166.69B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
686.02 | 57.12B | 4.17B | 1.03B | 940.22M | 12.61 |
|
IQV
Iqvia Holdings Inc
|
233.69 | 40.48B | 15.90B | 1.28B | 2.21B | 7.2842 |
|
A
Agilent Technologies Inc
|
135.83 | 39.59B | 6.95B | 1.30B | 1.15B | 4.5696 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-06-24 | Eingeleitet | Barclays | Overweight |
| 2025-04-04 | Herabstufung | Redburn Atlantic | Buy → Neutral |
| 2025-02-19 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-12-10 | Hochstufung | Jefferies | Hold → Buy |
| 2024-10-17 | Herabstufung | HSBC Securities | Buy → Hold |
| 2024-06-27 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-12-19 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-07 | Hochstufung | Goldman | Neutral → Buy |
| 2023-09-12 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-05-23 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-18 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-01-18 | Hochstufung | DZ Bank | Hold → Buy |
| 2021-10-15 | Fortgesetzt | Cowen | Market Perform |
| 2021-10-14 | Eingeleitet | Redburn | Buy |
| 2021-07-14 | Herabstufung | Kepler | Buy → Hold |
| 2021-06-03 | Eingeleitet | Goldman | Neutral |
| 2020-10-06 | Fortgesetzt | BofA Securities | Buy |
| 2020-09-28 | Hochstufung | Kepler | Hold → Buy |
| 2020-08-24 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-08-20 | Fortgesetzt | JP Morgan | Overweight |
| 2020-08-17 | Hochstufung | Berenberg | Hold → Buy |
| 2020-08-14 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2020-08-14 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2020-03-04 | Herabstufung | Berenberg | Buy → Hold |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Neutral |
| 2019-12-26 | Fortgesetzt | BofA/Merrill | Underperform |
| 2019-11-15 | Eingeleitet | Stifel | Hold |
| 2019-11-14 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-11-14 | Hochstufung | JP Morgan | Underweight → Overweight |
| 2019-11-14 | Hochstufung | Kepler | Reduce → Hold |
| 2019-10-17 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2019-10-09 | Herabstufung | Kepler | Hold → Reduce |
| 2019-10-08 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-10-08 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2019-10-08 | Herabstufung | JP Morgan | Neutral → Underweight |
Alle ansehen
Qiagen Nv Aktie (QGEN) Neueste Nachrichten
QIAGEN NV : DZ Bank reaffirms its Buy rating - marketscreener.com
QIAGEN NV : UBS gives a Neutral rating - marketscreener.com
Qiagen (QGEN) Soars 16.6%: Is Further Upside Left in the Stock? - Nasdaq
QIAGEN NV : Buy rating from Jefferies - marketscreener.com
Middle East Exosomes Market Research Report 2025-2033: Diagnostic and Therapeutic Adoption, R&D Investment, and Liquid Biopsy Demand Drive Growth - GlobeNewswire Inc.
Qiagen Said to Weigh Strategic Options Amid Fresh Interest - Bloomberg.com
Qiagen (QGEN) Hits 4-Year High as Earnings Loom - Insider Monkey
Qiagen (NYSE:QGEN) Sets New 52-Week HighStill a Buy? - MarketBeat
Qiagen (QGEN) Shares Surge Amid Takeover Speculation - GuruFocus
Agilent and Danaher Eye Qiagen Acquisition as Shares Surge 19% - Intellectia AI
Agilent, Danaher could be potential buyers of Qiagenanalyst (QGEN:NYSE) - Seeking Alpha
Qiagen stock price jumps nearly 16% as Bloomberg report revives sale talk - TechStock²
Qiagen gains on report it's weighing options amid takeover interest - MSN
Dutch biotech company soars: Rumors of discussions with potential buyers - medwatch.com
Qiagen (QGEN) Surges 12% Amid Potential Sale Discussions - GuruFocus
Qiagen (QGEN) Evaluates Sale Options Amid Takeover Interest, Shares Up 12% - Intellectia AI
Qiagen weighing strategic options amid fresh takeover interest, Bloomberg reports - Reuters
QIAGEN Stock Poised for Movement Amid Q4 Results Announcement - StocksToTrade
QGEN Stock Rises Amid Potential Sale Discussions - GuruFocus
Qiagen stock soars after report company weighing strategic options By Investing.com - Investing.com Nigeria
Qiagen stock soars after report company weighing strategic options - Investing.com
Qiagen Is Said to Consider Strategic Options Amid Fresh Interest - Bloomberg.com
QIAGEN N.V. to Release Results for Q4 2025 and Hold Webcast - sharewise.com
How to listen to QIAGEN’s Q4 2025 earnings webcast on Feb. 5 - Stock Titan
23,093 Shares in Qiagen N.V. $QGEN Purchased by SG Americas Securities LLC - MarketBeat
Qiagen N.V. $QGEN Shares Sold by Massachusetts Financial Services Co. MA - MarketBeat
Sumitomo Mitsui Trust Group Inc. Invests $7.29 Million in Qiagen N.V. $QGEN - MarketBeat
Qiagen N.V. (NYSE:QGEN) Short Interest Down 20.2% in December - MarketBeat
Campbell & CO Investment Adviser LLC Makes New Investment in Qiagen N.V. $QGEN - MarketBeat
Analysis Recap: Is Qiagen NV stock a smart retirement pickJuly 2025 Earnings & Safe Capital Investment Plans - baoquankhu1.vn
Qiagen Reports AFM Notification of Major Stake by Massachusetts Financial Services - TipRanks
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView — Track All Markets
Release according to Article 40, Section 1 of the WpHG - TradingView — Track All Markets
QIAGEN NV : Receives a Buy rating from DZ Bank - marketscreener.com
Qiagen N.V.: How a Quiet Diagnostics Powerhouse Became a Platform Bet on the Future of Medicine - AD HOC NEWS
Qiagen and Gencurix partner for oncology tests - MSN
Did Qiagen’s (QGEN) AI and Automation Push Just Redefine Its Diagnostics Investment Narrative? - simplywall.st
JPM26: Qiagen outlines key priorities to drive momentum in 2026 - Medical Device Network
Canada Next-Generation Sequencing (NGS) Market Analysis and Forecast, 2025-2035, Featuring Illumina, Oxford Nanopore Technologies, Pacific Bioscience of California, MGI Tech Co., QIAGEN and More - GlobeNewswire
Aug Momentum: How Qiagen NV stock performs in interest rate cycles2025 Big Picture & High Accuracy Swing Entry Alerts - Bộ Nội Vụ
QIAGEN Board Member’s Holdings Adjusted Following Share Consolidation - TipRanks
QIAGEN Adjusts Management Shareholdings Following Synthetic Share Repurchase - TipRanks
QIAGEN Adjusts Board Member Shareholding Following Synthetic Share Consolidation - TipRanks
QIAGEN discloses management share consolidation under synthetic repurchase program - TipRanks
QIAGEN adjusts insider shareholdings after synthetic share repurchase and consolidation - TipRanks
QIAGEN adjusts board member shareholding after synthetic share consolidation - TipRanks
PTA-DD: QIAGEN N.V.: Managers' transactions announcement according to article 19 MAR - TradingView — Track All Markets
Qiagen N.V.: Diagnostics Specialist Tests Investor Patience Amid Sideways Trading and Selective Opti - AD HOC NEWS
Qiagen (QGEN) is a Top-Ranked Momentum Stock: Should You Buy? - Yahoo Finance
QIAGEN Sets 2026 Priorities to Drive Growth Across Five Pillars Toward Achieving 2028 Goals for Solid Profitable Growth - BioSpace
QIAGEN Sets 2026 Priorities to Drive Growth Across Five Pillars Toward Achieving 2028 Goals for Soli - PharmiWeb.com
Finanzdaten der Qiagen Nv-Aktie (QGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.90%
0.91%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):